FDA raises concern over drug production process at Cadila

MUMBAI Thu Jul 31, 2014 4:20pm IST

Related Topics

Stocks

   

MUMBAI (Reuters) - Cadila Healthcare Ltd (CADI.NS) is responding to certain observations the U.S. Food and Drug Administration (FDA) made after conducting a "product specific" inspection of its Moraiya manufacturing plant, a company spokeswoman said on Thursday.

Sources with direct knowledge told Reuters earlier that the FDA expressed concerns over the manufacturing process of at least one product at Cadila's Moraiya facility in the western Indian state of Gujarat.

"This was a product specific review and the inspection was limited to the review of documents for filed ANDA before its approval and the observations are being responded to," the Cadila spokeswoman said in a statement.

ANDA is an application drugmakers file with the FDA seeking approval to launch a new generic drug.

There is no business impact from the FDA action and Cadila has not received any observations on the standard manufacturing practices at the Moraiya plant, the spokeswoman said.

She did not immediately respond to a request seeking details on the inspection.

The FDA communicated its concern to Cadila in a Form 483, the company spokeswoman said. A Form 483 is a letter the agency issues after completing an inspection to outline conditions that the FDA believes violate standard regulations.

Once a Form 483 is issued by the FDA, the company has 15 days to respond before the FDA takes further action.

Cadila, among India's top 10 drugmakers, has one of the largest pipelines of 158 generic drugs awaiting approval from the FDA, according to company filings.

Cadila's shares dropped as much as 10.5 percent on Thursday. The stock ended down 4.5 percent at 1,116.15 rupees, while the Nifty fell 0.9 percent.

Separately, Citigroup on Thursday downgraded Cadila's stock to "sell" from "buy", saying the company's valuations have moved well ahead of its fundamentals. Indian brokerage IDBI Capital also cut its rating on Cadila stock to "accumulate" from "buy".

(Editing by Sumeet Chatterjee and Matt Driskill)

FILED UNDER:

Reuters Showcase

Land Ordinance

Land Ordinance

Modi says willing to make changes in land decree  Full Article 

Sahara Woes

Sahara Woes

SEBI cancels Sahara's portfolio management licence  Full Article 

Gold Demand

Gold Demand

India gold demand muted, eyes cut in import duty  Full Article 

Coffee's Hot

Coffee's Hot

IPO could value Cafe Coffee Day at $1 billion  Full Article 

Sahara Salaries

Sahara Salaries

Some staff say Sahara has not paid salaries for months   Full Article 

DLF Fined

DLF Fined

DLF says reviewing $8.4 million SEBI penalty  Full Article 

GM Corn

GM Corn

Monsanto says GM corn trial in final stage in India  Full Article 

Rail Budget

Rail Budget

Breakingviews - India goes back to future with $137 bln rail push  Full Article | Full Coverage 

Clean Energy

Clean Energy

India says clean energy a $160 billion opportunity over five years  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage